NervGen Pharma Corp. (NGEN) — Cash Flow-to-Debt Ratio
NervGen Pharma Corp. (NGEN) has a Cash Flow-to-Debt Ratio of -0.55x as of March 2026, meaning its operating cash flow of $-8.34 Million could theoretically repay -1% of its total liabilities ($15.21 Million) in one year. Explore NervGen Pharma Corp. (NGEN) long-term investment share to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
NervGen Pharma Corp. Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for NervGen Pharma Corp. across 8 annual periods. Also explore NervGen Pharma Corp. balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for NervGen Pharma Corp. (2018–2025)
Year-by-year debt coverage analysis for NervGen Pharma Corp.. For market capitalisation and broader financial context, see NervGen Pharma Corp. (NGEN) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.99x | $-19.50 Million | $19.73 Million | ▲ +0.8% |
| 2024 | -1.00x | $-16.83 Million | $16.90 Million | ▼ -34.4% |
| 2023 | -0.74x | $-11.30 Million | $15.25 Million | ▲ +56.6% |
| 2022 | -1.71x | $-17.63 Million | $10.32 Million | ▲ +77.7% |
| 2021 | -7.67x | $-8.33 Million | $1.09 Million | ▲ +8.2% |
| 2020 | -8.35x | $-6.32 Million | $756.78K | ▲ +4.7% |
| 2019 | -8.76x | $-8.31 Million | $949.14K | ▼ -391.1% |
| 2018 | -1.78x | $-1.04 Million | $581.26K | — |